# Phase 2 syndrome trials recruiting: 225 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 225 trials in phase 2 for syndrome that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 syndrome trials: 225 rows for $11.25, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 7 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/syndrome

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 225
- Recruiting or not yet: 225
- Read on: November 19, 2026

## Trials

The 25 newest of 225, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07946796 | Semaglutide Effects on Sperm Concentration in Overweight Infertile Men | Copenhagen University Hospital at Herlev | Phase 2 | Not yet recruiting | Infertility in Overweight Men | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07946796) |
| November 12, 2026 | NCT07930637 | Rimonabant for Cognitive Impairment in People With Post-COVID-19 Syndrome | Sinfatin S.L | Phase 2 | Not yet recruiting | Post-COVID-19 Syndrome | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07930637) |
| November 12, 2026 | NCT07930520 | A Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of S247240 in Adult Male Participants With Fragile X Syndrome | Institut de Recherches Internationales Servier (I.R.I.S.) | Phase 2 | Not yet recruiting | Fragile X Syndrome (FXS) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07930520) |
| November 6, 2026 | NCT07922148 | Osilodrostat for Glycemic Control in Mild Autonomous Cortisol Secretion (MACS) With Difficult-To-Control Type 2 Diabetes - A Randomized... | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Mild Autonomous Cortisol Secretion (MACS), Diabetes Mellitus (Type 2) | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922148) |
| October 29, 2026 | NCT07903441 | Multiple Interventions With Distinct Anti-reservoir Activities in People on Antiretroviral Treatment | Federal University of São Paulo | Phase 2 | Recruiting | HIV - Human Immunodeficiency Virus | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903441) |
| October 29, 2026 | NCT07902752 | Oxytocin for Respiratory Compromise and Hypoventilation Induced by Drugs | George Washington University | Phase 2 | Not yet recruiting | Obesity & Overweight, Respiratory Depression, Intranasal Drug Administration, Oxytocin, Bariatric Surgery | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902752) |
| October 27, 2026 | NCT07899346 | Study of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination Syndrome | Invivyd, Inc. | Phase 2 | Not yet recruiting | Long COVID, COVID-19 (SARS-CoV-2 Infection), COVID 19 Vaccine, COVID Long | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899346) |
| October 19, 2026 | NCT07881809 | A Clinical Study of Ixazomib to Reactivate HIV and Reduce HIV Reservoir Size | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | Not yet recruiting | HIV (Human Immunodeficiency Virus) | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881809) |
| October 13, 2026 | NCT07871669 | Efficacy and Safety of TRA16 Administered Orally in Patients With Enteric Hyperoxaluria (EH). | Wuhan Kangfude Urolithiasis Research Institute Co., Ltd. | Phase 2 | Not yet recruiting | Enteric Hyperoxaluria | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871669) |
| October 1, 2026 | NCT07852728 | HBOT Effects on First Responders' Cognition and Well-Being | Sponsor not shown (see the record) | Phase 2 | Recruiting | Traumatic Brain Injury, PTSD - Post Traumatic Stress Disorder, Anxiety, Depression, Post Concussion Symptoms | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07852728) |
| October 1, 2026 | NCT07851337 | Immunotherapy With Glatiramer Acetate in PLWHIV in Poor Immunological Responders on Antiretroviral Therapy | ANRS, Emerging Infectious Diseases | Phase 2 | Not yet recruiting | HIV - Human Immunodeficiency Virus | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07851337) |
| September 30, 2026 | NCT07849465 | Hyperbaric Oxygen Therapy for Veterans With TBI and PCS: A Biomarker Study | Sponsor not shown (see the record) | Phase 2 | Recruiting | Traumatic Brain Injury (TBI) Patients, Post Concussive Symptoms, PTSD | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07849465) |
| September 24, 2026 | NCT07838454 | Exosome and Mesenchymal Stem Cell Treatment for Salivary Gland Dysfunction in Primary Sjögren Syndrome | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Sjogren Syndrome, Xerostomia, Exosome | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07838454) |
| September 23, 2026 | NCT07836660 | A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease | Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 | Not yet recruiting | Sjögren's Disease | 198 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07836660) |
| September 22, 2026 | NCT07833163 | Corticotropin for Behçet's Disease: A Multicenter Randomized Controlled TrialAcronym. | Peking University People's Hospital | Phase 2 | Not yet recruiting | Behçet's Syndrome, Behçet's Syndrome (BS) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07833163) |
| September 16, 2026 | NCT07823790 | ONO-4915 in Patients With Primary Sjogren's Disease | Ono Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Sjogren's Disease | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07823790) |
| September 16, 2026 | NCT07822607 | Intravenous Iron in the Management of Drug-resistant Restless Legs syndromeI | University Hospital, Montpellier | Phase 2 | Not yet recruiting | Restless Legs Syndrome (RLS) | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07822607) |
| September 16, 2026 | NCT07821762 | A Study of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré Syndrome | argenx | Phase 2 | Not yet recruiting | Guillain-Barré Syndrome (GBS) | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07821762) |
| September 10, 2026 | NCT07812181 | An Open-Label Phase II Feasibility Study for the Use of Ublituximab in Adults With Down Syndrome Regression Disorder | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Down Syndrome Regression Disorder (DSRD), Down Syndrome (Trisomy 21), Neuroinflammatory / Neuropsychiatric Disorder | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07812181) |
| September 8, 2026 | NCT07807163 | A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC | Bicara Therapeutics | Phase 2 | Recruiting | Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807163) |
| September 8, 2026 | NCT07806916 | Efficacy and Safety of Efgartigimod in the Treatment of Guillain-Barré Syndrome(GREAT) | Beijing Tiantan Hospital | Phase 2 | Not yet recruiting | Guillain-Barré Syndrome | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07806916) |
| August 25, 2026 | NCT07784582 | Pre-pubertal Low Dose Transdermal Estradiol in Turner Syndrome | Children's National Research Institute | Phase 2 | Not yet recruiting | Turner Syndrome, Primary Ovarian Insufficiency | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07784582) |
| August 18, 2026 | NCT07771855 | Efficacy of an Anti-TSLP Monoclonal Antibody in the Management of Chronic Bronchial Disease Induced by Bronchiolitis Obliterans Syndrome in... | Hopital Foch | Phase 2 | Recruiting | Bronchiolitis Obliterans Syndrome (BOS), HSCT, Bronchial Disease | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07771855) |
| August 17, 2026 | NCT07768267 | Herbal Supplement (Biocidin REMOVE) for Bacterial Overgrowth in Irritable Bowel Syndrome | Johns Hopkins University | Phase 2 | Recruiting | Irritable Bowel Syndrome (IBS), Small Intestinal Bacterial Overgrowth Syndrome (SIBO) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07768267) |
| August 11, 2026 | NCT07756736 | Psilocybin Therapy for Methamphetamine Use Disorder and HIV | Sponsor not shown (see the record) | Phase 2 | Recruiting | Methamphetamine Use Disorder, Human Immunodeficiency Virus (HIV) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07756736) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National Institute of Allergy and Infectious Diseases (NIAID) | 4 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 4 |
| PPD Development, LP | 4 |
| Institute of Hematology & Blood Diseases Hospital, China | 4 |
| Mayo Clinic | 3 |
| Icahn School of Medicine at Mount Sinai | 3 |
| VA Office of Research and Development | 3 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 3 |
| Vanderbilt University Medical Center | 3 |
| National Cancer Institute (NCI) | 3 |
| Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 2 |
| [ImmunityBio, Inc.](https://specstream.ai/data/clinical-trials/company/immunitybio-inc) | 2 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 2 |
| Holland Bloorview Kids Rehabilitation Hospital | 2 |
| Université de Sherbrooke | 2 |
| University of Colorado, Denver | 2 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2 |
| Peking University People's Hospital | 2 |
| University of Calgary | 2 |
| Shanghai Zhongshan Hospital | 2 |
| ANRS, Emerging Infectious Diseases | 2 |
| University of Minnesota | 2 |
| Federal University of São Paulo | 2 |
| Brigham and Women's Hospital | 2 |
| Peking Union Medical College Hospital | 2 |

## By country

| Country | Trials |
| --- | --- |
| United States | 120 |
| China | 27 |
| France | 22 |
| Canada | 18 |
| Italy | 16 |
| Spain | 15 |
| Germany | 14 |
| United Kingdom | 13 |
| Australia | 11 |
| Belgium | 9 |
| Poland | 8 |
| Netherlands | 8 |
| Mexico | 5 |
| Japan | 5 |
| Israel | 5 |
| Brazil | 5 |
| Singapore | 4 |
| South Korea | 4 |
| Hungary | 4 |
| Taiwan | 4 |
| Denmark | 3 |
| Turkey (Türkiye) | 3 |
| Bulgaria | 3 |
| Romania | 3 |
| Colombia | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Fireplace services in the United States](https://specstream.ai/data/businesses/fireplace-services/united-states)
- [Water utilities in the United States](https://specstream.ai/data/businesses/water-utilities/united-states)
- [Lawn care companies in the United States](https://specstream.ai/data/businesses/lawn-care-companies/united-states)
- [Bookkeeping firms in the United States](https://specstream.ai/data/businesses/bookkeeping-firms/united-states)
- [Pool cleaning companies in the United States](https://specstream.ai/data/businesses/pool-cleaning-companies/united-states)
- [Electrical supply stores in the United States](https://specstream.ai/data/businesses/electrical-supply-stores/united-states)
